

FLUOROURACIL with concurrent RT

INDICATION (ICD10) C25

1. Locally advanced pancreatic cancer. PS 0, 1, 2

REGIMEN

Days 1, 8, 15, 22 and 29

FLUOROURACIL 225mg/m²/24 (1575mg/m²/7days) hours continuous IV infusion over 7 days

CYCLE FREQUENCY AND NUMBER OF CYCLES

Continuously for 5 weeks during radiotherapy

ANTI-EMETICS

Low emetogenic risk

CONCURRENT MEDICATION REQUIRED

Fluorouracil	Mouth and bowel support eg_Loperamide, benzydamine mouthwash
--------------	--

EXTRAVASATION AND TYPE OF LINE / FILTERS

Fluorouracil - inflammitant

Central (double lumen)

INVESTIGATIONS

Blood results required before SACT administration

FBC, U&E and LFTs every cycle

Neutrophils x $10^9/L \ge 1.5$ (1-1.5 discuss with Consultant)

Platelets x 10⁹/L ≥100 (75-100 discuss with Consultant)

Serum creatinine

ECG (possible ECHO) required if patient has preexisting cardiac disease

DPD test

Baseline weight and every cycle

MAIN TOXICITES AND ADVERSE REACTIONS

Fluorouracil	Palmar plantar (handfoot syndrome) causing red palms and soles – treat with
	pyridoxine 50mg tds
	Diarrhoea – treat with loperamide or codeine
	Cardiotoxicity – monitor cardiac function. Special attention is advisable in
	treating patients with a history of heart disease, arrhythmias or angina
	pectoris or those who develop chest pain during treatment with fluorouracil.
	Stomatitis

INTERACTIONS WHICH MAY REQUIRE DOSE MODIFICATIONS

(not exhaustive list check SPC/BNF/Stockleys)

<u></u>			
Fluorouracil Cimetidine slightly increases exposure to fluorouracil			
	Metronidazole increased toxicity		
Phenytoin concentration increased			
	Warfarin		

Fluorouracil with RT	Upper GI CAG approval	Page 1 of 2	Approved: June 2021	Version
			Review: June 2023	5.0



DOSE MODIFICATIONS

Fluorouracil

The fluorouracil course should be delayed for a week or until completely recovered in the event of either low blood counts (neutrophils $<1.5x10^9$ or platelets $<100x10^9$) or any persistent mucositis or diarrhoea.

Non-haematological toxicity (CTC	0-1	2	3	4
grade): diarrhoea, stomatitis				
Haematological toxicity (x10 ⁹ /L):	100%	80%	50%	No further
Platelets ≥50 and neutrophils ≥1.0				treatment
Haematological toxicity (x10 ⁹ /L):	80%	70%	50%	No further
Platelets 25-49 or neutrophils 0.5-0.9				treatment
Haematological toxicity (x10 ⁹ /L):	50%	50%	50%	No further
Platelets <25 or neutrophils <0.5				treatment

Hepatic impairment

Fluorouracil

Significantly impaired hepatic function eg bilirubin >50micromol/L may be a sign of disease progression and require cessation of, or change in, treatment. Always discuss deteriorating liver function with consultant.

Bilirubin >85micromoi/L not recommended

Renal impairment

Fluourouracil

CrCl >30ml/min	give 100% dose		
CrCl <30ml/min	consider dose reduction		

REFERENCES

Fluorouracil with RT	Upper GI CAG approval	Page 2 of 2	Approved: June 2021	Version
			Review: June 2023	5.0